- Home
- FLYE vs ERNA Comparison
FLYE vs ERNA Comparison
Compare FLYE & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | ERNA |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 10.0M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | FLYE | ERNA |
|---|---|---|
| Price | $7.95 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 234.5K | 39.5K |
| Earning Date | 02-18-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,966,391.00 | $1,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.83 | $1.08 |
| 52 Week High | $161.80 | $14.40 |
Technical Indicators
Market Signals| Indicator | FLYE | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.67 | 42.30 |
| Support Level | $5.81 | $1.08 |
| Resistance Level | $8.99 | $1.29 |
| Average True Range (ATR) | 0.87 | 0.09 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 71.16 | 36.00 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.